Don’t ask me why or how, but every now and then I get a clinical trial budget that I have never seen before, nor am I able to compare it to anything else that is remotely similar. My strategy for these situations (and these situations only) seems to usually get the job done. Let me know your thoughts and sorry about the glare, I don’t know what I was thinking
The question is self-explanatory, but a good one nonetheless. Do sub investigators get paid by clinical research facilities, what do they do, and how do most research clinics typically structure sub investigator payments?
In this week’s full length podcast, I dive into the viewer question box and pull out some interesting topics. The first is how CRO’s and Sponsors ensure that PI’s are truly reading the Serious Adverse Event Reports that they send to all research sites, or whether they are just signing and filing. The next question is how to tell the difference between a CRO and an SMO in clinical research. Another topic is PI availability versus the Sponsor’s ever increasing demands for more PI oversight and what we can expect in 2014 and 2015 in this industry. There are other topics I cover here as well and I hope you find some value out of it.
The title is self-explanatory but it is derived from a question I received on Twitter regarding this article.
This week’s podcast/video has me digging in the Guru grabag of emails and answering several of your questions. I focus on risk-based monitoring, recruitment strategies, how Sponsors are using low study supply to pit CRO’s against each other and a whole lot more including the fact that CRA’s have no life! I hope you enjoy and remember to send your questions my way anonymously for your question to possibly get answered on video!
In today’s video I share some anecdotal evidence of a particular trend I am seeing as of late in clinical research: Sponsors choosing two CRO’s to conduct virtually the same protocol and then, through risk-based monitoring, assessing which protocol they want to stick with (if any) and which study they will cancel. I have seen this personally occur three times this year while hearing the same from others in the industry at both the research site and CRO level. I do not believe this is a long term trend, rather I see this as a direct result of the relatively low supply of clinical trials this year and the high demand amongst CRO’s to want to win these studies. When study activity picks up next year, I think we will see less of this but at least for now, this is what we have to deal with.